[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar",
    "summary": "Bristol-Myers Squibb Company's undervaluation offers over 20% upside potential despite headwinds. Click here to find out why BMY stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=579839060b5b1f73d821cb982f01d138e1a0769dcb08b9e246ff07a26b38c33b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748364159,
      "headline": "Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar",
      "id": 134716166,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1832921718/image_1832921718.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company's undervaluation offers over 20% upside potential despite headwinds. Click here to find out why BMY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=579839060b5b1f73d821cb982f01d138e1a0769dcb08b9e246ff07a26b38c33b"
    }
  },
  {
    "ts": null,
    "headline": "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place",
    "summary": "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place",
    "url": "https://finnhub.io/api/news?id=cc007612ccff6c3d3a92a4c004d50f3b0433ec6287a08cca0b137bde8e86d895",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748360877,
      "headline": "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place",
      "id": 134714924,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=cc007612ccff6c3d3a92a4c004d50f3b0433ec6287a08cca0b137bde8e86d895"
    }
  },
  {
    "ts": null,
    "headline": "Merck Proves Why It's Still A Top Pharma Pick",
    "summary": "Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg.",
    "url": "https://finnhub.io/api/news?id=0cd74fb2506cf79a35bbc4e590465ab9d359d893b4ba9d191509d006f7ab888a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748360766,
      "headline": "Merck Proves Why It's Still A Top Pharma Pick",
      "id": 134714927,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662733/image_1357662733.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg.",
      "url": "https://finnhub.io/api/news?id=0cd74fb2506cf79a35bbc4e590465ab9d359d893b4ba9d191509d006f7ab888a"
    }
  },
  {
    "ts": null,
    "headline": "Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down",
    "summary": "PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.",
    "url": "https://finnhub.io/api/news?id=082174c39144c14d364d03e957aa1e9565ed5a3224b5d5a854ec54366416753a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748355600,
      "headline": "Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down",
      "id": 134716441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.",
      "url": "https://finnhub.io/api/news?id=082174c39144c14d364d03e957aa1e9565ed5a3224b5d5a854ec54366416753a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Canada Says New Subcutaneous Formulation Of Opdivo Approved In Canada",
    "summary": "Bristol-Myers Squibb Canada: * BRISTOL-MYERS SQUIBB CANADA: NEW SUBCUTANEOUS FORMULATIONOFOPDIVO APPROVED IN CANADA FOR USE ACROSS ALL AUTHORIZED SOLIDTUMOUR INDICATIONSSource...",
    "url": "https://finnhub.io/api/news?id=1cfd93684b670720652f372aa6f7a620ddd9d0b79ce82e6ae8650bb43c55e863",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748353447,
      "headline": "Bristol-Myers Squibb Canada Says New Subcutaneous Formulation Of Opdivo Approved In Canada",
      "id": 134710061,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol-Myers Squibb Canada: * BRISTOL-MYERS SQUIBB CANADA: NEW SUBCUTANEOUS FORMULATIONOFOPDIVO APPROVED IN CANADA FOR USE ACROSS ALL AUTHORIZED SOLIDTUMOUR INDICATIONSSource...",
      "url": "https://finnhub.io/api/news?id=1cfd93684b670720652f372aa6f7a620ddd9d0b79ce82e6ae8650bb43c55e863"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%",
    "summary": "BMY stock offers value with a sub-7x P/E, 6% dividend yield, and strong earnings. Discover why itâs a compelling buy despite sector challenges.",
    "url": "https://finnhub.io/api/news?id=06c3225bc4b70a1b9478d746c6f16053c26040c0ef3eb46a9327a7c44aba194c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748348194,
      "headline": "Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%",
      "id": 134709621,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BMY stock offers value with a sub-7x P/E, 6% dividend yield, and strong earnings. Discover why itâs a compelling buy despite sector challenges.",
      "url": "https://finnhub.io/api/news?id=06c3225bc4b70a1b9478d746c6f16053c26040c0ef3eb46a9327a7c44aba194c"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Income Stock Fund Q1 2025 Commentary",
    "summary": "BNY Mellon Income Stock Fund (Class A at NAV) returned 3.11% during the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=daa65f5c3dbc517f6c21c1e66b32a2b50aec8c1b7dc22bd14c2abe6bbb05afde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748340060,
      "headline": "BNY Mellon Income Stock Fund Q1 2025 Commentary",
      "id": 134708851,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1881807987/image_1881807987.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BNY Mellon Income Stock Fund (Class A at NAV) returned 3.11% during the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=daa65f5c3dbc517f6c21c1e66b32a2b50aec8c1b7dc22bd14c2abe6bbb05afde"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence",
    "summary": "Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's received approval. Read why BMY earns a Strong Buy upgrade.",
    "url": "https://finnhub.io/api/news?id=a41431c2d4892c93c6a1f427c58b54bbb57173440bfde20a0424a9348bd7a705",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748337274,
      "headline": "Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence",
      "id": 134708601,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/640215102/image_640215102.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's received approval. Read why BMY earns a Strong Buy upgrade.",
      "url": "https://finnhub.io/api/news?id=a41431c2d4892c93c6a1f427c58b54bbb57173440bfde20a0424a9348bd7a705"
    }
  },
  {
    "ts": null,
    "headline": "Lazard Managed Equity Volatility Portfolio Q1 2025 Commentary",
    "summary": "During the quarter, the Lazard Global Managed Volatility Equity Portfolio underperformed the MSCI World Index (net of fees).",
    "url": "https://finnhub.io/api/news?id=c3b309b095d6329cb51d8d085774dc394cbe090d05bac9b4431e895bfe656da4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748305800,
      "headline": "Lazard Managed Equity Volatility Portfolio Q1 2025 Commentary",
      "id": 134705456,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357752804/image_1357752804.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "During the quarter, the Lazard Global Managed Volatility Equity Portfolio underperformed the MSCI World Index (net of fees).",
      "url": "https://finnhub.io/api/news?id=c3b309b095d6329cb51d8d085774dc394cbe090d05bac9b4431e895bfe656da4"
    }
  }
]